Effects of Sacubitril/Valsartan According to Natriuretic Peptide Levels in Patients Enrolled in PARADIGM-HF and PARAGON-HF
The relative risk reductions with sacubitril/valsartan were consistent irrespective of NT-proBNP level in HF patients across the range of LVEF. Consequently, the absolute risk reductions were greatest in patients with higher NT-proBNP levels. (PARADIGM-HF [Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor with Angiotensin-Converting-Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial]; NCT01035255; and PARAGON-HF [Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor with Angiotensin-Receptor Blockers Global Outcomes in HF with Preserved Ejection Fraction]; NCT01920711).
Authors
- Inder S. Anand (ORCID: https://orcid.org/0000-0003-1308-4963)
- Kieran F. Docherty (ORCID: https://orcid.org/0000-0002-5446-9969)
- Brian Lee Claggett (ORCID: https://orcid.org/0000-0002-4215-9218)
- Pardeep S. Jhund (ORCID: https://orcid.org/0000-0003-4306-5317)
- John J.V. McMurray (ORCID: https://orcid.org/0000-0002-6317-3975)
- Margaret M. Redfield (ORCID: https://orcid.org/0000-0002-0946-7518)
- Felipe A. Martínez (ORCID: https://orcid.org/0000-0002-5836-972X)
- Faiez M. Zannad (ORCID: https://orcid.org/0000-0001-7456-1570)
- Milton Packer (ORCID: https://orcid.org/0000-0003-1828-2387)
- Michael R. Zile (ORCID: https://orcid.org/0000-0001-7076-221X)
- Toru Kondo (ORCID: https://orcid.org/0000-0001-6853-7574)
- Martin Lefkowitz
- Aldo P. Maggioni (ORCID: https://orcid.org/0000-0003-2764-6779)
- Akshay S. Desai (ORCID: https://orcid.org/0000-0002-1443-0701)
- Dirk Jan van Veldhuisen
- Carolyn Lam
- Scott Solomon
- Jean L. Rouleau (ORCID: https://orcid.org/0009-0004-0592-8091)
Institutions
- Brigham and Women's Hospital (US)
- University of Minnesota (US)
- Mayo Clinic (US)
- University Medical Center Groningen (NL)
- Harvard University (US)
- Medical University of South Carolina (US)
- National University of Singapore (SG)
- University of Groningen (NL)
- Montreal Heart Institute (CA)
- Baylor University Medical Center (US)
- British Heart Foundation (GB)
- Associazione Nazionale Medici Cardiologi Ospedalieri (IT)
- National University Heart Centre Singapore (SG)
- Novartis (United States) (US)
- Minneapolis VA Medical Center (US)
- National Heart Centre Singapore (SG)
- French Clinical Research Infrastructure Network (FR)
- Université de Montréal (CA)
- University of Glasgow (GB)
- Université de Lorraine (FR)
Publication Details
- Journal
- JACC Heart Failure
- Published
- 2025-03-12
- DOI
- https://doi.org/10.1016/j.jchf.2024.12.010
- Citations
- 9
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 12.49
Funders
- Amgen
- AstraZeneca
- Bayer
- Alnylam Pharmaceuticals
- Novartis Pharmaceuticals Corporation
- Boston Scientific Corporation
- Abbott Japan
- Regeneron Pharmaceuticals
- LivaNova
- Kowa Company
- British Heart Foundation
- Great Britain Sasakawa Foundation
- University of Glasgow
- Ono Pharmaceutical
- Intas Pharmaceuticals
- Novartis Pharma
- Relypsa